FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation

FDA approves new biologic for chronic rhinosinusitis with nasal polyps

The FDA on Friday approved a new biologic as add-on maintenance treatment for inadequately controlled chronic rhinosinusitis with nasal polyps, according to Amgen and AstraZeneca.Tezspire (tezepelumab-ekko) is approved for patients aged 12 years or older, the companies announced in a press release.

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 1...